CEO Corner
CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of. To submit a CEO Corner article, please follow these guidelines.
-
Recognizing The Value Of Biotech Partnerships In China
China’s pharmaceutical market operates under regulations that are closely aligned with world standards, and the companies making innovative in-roads into the market are fueled by regional and international biotech finance.
-
An Intentionally Unconventional Journey To CEO
I am glad to share my history here in hopes to spark a dialogue on how life science leaders are shaped, how contributions from “all paths” provide new perspectives, and how the benefits of nonconformity can improve future views — and functions therein — of leadership.
-
From CRO Executive To Biopharma CEO
Taking over the CEO position of a biopharma in the midst of COVID, I was faced with many unique challenges. While I continue to work through these challenges, I’ve developed guidelines that have played a pivotal role in navigating such transitions.
-
What I Learned In A French Lab That Led To My Role As A CEO
Our innovations didn’t happen overnight. From the very beginning, we knew that we would need to partner with others to be successful.
-
The Key To Competitive Differentiation In Life Sciences Is People
Especially in the early stage of a company, where speed and accuracy of drug development are highly valued, focusing on organizational strategies that provide differentiation enables a company to position itself as innovative.
-
Embracing Culture As A Strategic Business Asset
I believe that my recognition of the role company culture plays in shaping an organization has contributed to my success as my career advanced into leadership roles.
-
Is It A Great Business Opportunity Or Merely A Great Idea?
When entrepreneurs are presented with a biotech idea, they must distinguish between those that are merely exciting in concept and those with the potential to be actually developed into a company.
-
Skills I Learned That Have Helped Me As A Public Pharma CEO
While I learned a great deal about the industry in the latter part of my career, as a leader, my foundation was molded by the valuable lessons learned in two very different spaces — the U.S. Army Reserve and nursing.
-
Creating A Culture of Innovation In Any Size Organization
A company’s size and culture play a large role in how it defines and executes innovation.
-
What The Sale Of Agios’ Oncology Pipeline Taught Me
Anytime a company undergoes organizational change — even if it’s a good change — the road there is not necessarily an easy one. I’d like to share a few things that might make it — or any major decision — easier for you
IN THIS MONTH'S ISSUE
BEYOND THE PRINTED PAGE
-
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
-
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
-
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
LIFE SCIENCE LEADER BLOGS
-
The decision by J.P. Morgan to make the 2022 annual healthcare conference fully virtual, inspires reflection on the past and advocacy for the future, in this final blog by Rob Wright, retired chief editor, Life Science Leader.
-
Three biopharmaceutical executives discuss plans around their company getting back to in-office operations.